Healthcare communications studio
Meridian Bridge is a specialist studio for the clinical, regulatory, and investor-facing content that complex healthcare and life-sciences organisations cannot afford to get wrong — and for the plain-language work that makes sure that content actually reaches the people it was written for.
Why plain language matters
Regulators now require it.
The EU Clinical Trials Regulation, SAHPRA guidance, and major funders including Wellcome and the NIH now mandate plain-language summaries of trial results — not as a courtesy, but as a condition of approval and continued funding. Organisations that cannot produce compliant plain-language documents face delays to submissions and jeopardise funder relationships.
Patients who understand their treatment take it.
Health literacy directly affects treatment adherence. A patient who cannot understand their information leaflet cannot give meaningful informed consent — and is statistically less likely to complete their treatment. In a region where HIV, TB, and non-communicable diseases co-exist at high rates, this is not an abstract concern.
Investors who can't parse the science don't allocate capital.
A pipeline narrative that reads like a protocol section will not move a generalist institutional investor or a family office dipping into biotech for the first time. Translating mechanism into implication — without losing scientific rigour — is the difference between a deal that closes and one that stalls at the first LP question.
What we do
01
Pipeline summaries, fundraising decks, annual report clinical sections, and CEO letters ahead of data readouts. We turn scientific complexity into the language investors use to allocate capital — without overclaiming, and without losing the rigour your science depends on.
02
Patient information leaflets, informed consent forms, plain-language summaries of trial results, and ethics-committee–ready documentation — written at the reading level that SAHPRA, the EU CTR, and major funders require. This is the work that gets delayed most often, costs the least to do well, and matters most to the patient sitting across the desk from a clinician who is trying to explain a trial they may not fully understand themselves.
03
HCP-facing educational material, disease-awareness content, and internal scientific communications. Built to be accurate enough for medical sign-off, and clear enough that a non-specialist reader actually finishes the page.
Why a studio
Most healthcare communications work is written by generalists who learn just enough science to be plausible. We do the opposite. That means the first draft is structured for medical, legal, and regulatory sign-off — not polished into compliance at the end.
A single senior writer on your work.
No account-management layer. No junior drafting then senior editing. You are talking, end-to-end, with the person writing your document.
Specialist focus.
We do not do brand campaigns, social-media strategy, event production, or general PR. We do the three things above, well.
Built for regulated environments.
Our work is structured for medical, legal, and regulatory sign-off from the first draft. We expect to be edited; we make it cheap to do so.
About
Meridian Bridge exists because the gap between what the science says and what audiences can act on is where good research stalls, good drugs get delayed, and good companies fail to raise capital. Closing that gap — precisely, rigorously, and without talking down to anyone — is the studio's entire purpose.
The studio was founded by Erin Nel, whose background spans academic research in neuroscience and psychology, behavioural science, and strategic communications. That combination — scientific rigour meeting audience intelligence — shapes every document Meridian Bridge produces.
Erin writes independently on medtech, neurotech, and health technology at Substack (@erinnel) — keeping the studio's work current with the leading edge of the field.
Based in Cape Town, South Africa. Working across the continent and beyond.
How we work
01
Free, 30 minutes. We listen to the document, the audience, the deadline, and the constraints. If we're not the right fit, we'll say so — and point you somewhere that is.
02
A written proposal with a fixed price, a fixed delivery date, and a fixed number of revision rounds. No hourly billing surprises.
03
A first draft within the agreed turnaround, then two structured rounds of revision built around how regulated organisations actually sign off documents.
Portfolio
Plain-language clinical trial summary
Written for an ethics-committee submission and funder report. Summarises the Lancet-published Sisonke study for a public audience at a grade 9 reading level.
Read sampleSeries B pipeline narrative
Clinical and pipeline section for a Series B fundraising deck. Audience: specialist biotech investors, institutional allocators, and pharmaceutical BD leads.
Read samplePatient information leaflet
Plain-language PIL for a fictional SGLT2 inhibitor (empagliflozin class), written for SAHPRA submission and patient-facing packaging insert. Grade 6–8 reading level.
Read sampleInformed consent form
Key patient-facing sections of an informed consent form for a fictional Phase 2b TB trial. Written for Wits/UCT HREC submission, GCP-compliant, grade 6–8 reading level.
Read sampleDisease-awareness patient FAQ
Patient-facing FAQ on U=U for a pharmaceutical medical-affairs team or HIV-focused NGO. Written for clinic hand-outs, NGO websites, and patient-education staff training.
Read samplePlain-language observational study summary
Funder report and community-feedback summary for a Lancet Global Health–published study on HIV, TB, diabetes, and hypertension co-occurrence in rural KwaZulu-Natal.
Read sampleContact
Send us a line about the document, the audience, and the deadline. We reply within one working day. The first conversation is free, and there's no obligation beyond it.
Get in touch
Send a sentence or two about the document, the audience, and the deadline — that's all we need to come back to you with something useful.